Research Article
Safety Assessment of Zigbir®: A Polyherbal Formulation in Sprague-Dawley Rats
Table 2
Haematological findings (mean ± SD) in male rats after 90 days subchronic oral administration of Zigbir®.
| Parameters | Control | 250 mg/kg | 500 mg/kg | 1000 mg/kg | Control recovery | 1000 mg/kg recovery |
| Hb (g%) | 15.15 ± 1.45 | 15.39 ± 0.60 | 15.07 ± 0.59 | 14.89 ± 0.99 | 16.34 ± 1.60 | 16.50 ± 0.83 | Total RBC (×106/L) | 7.00 ± 0.82 | 8.52** ± 0.60 | 7.50 ± 0.53 | 7.51 ± 0.50 | 8.35 ± 0.93 | 8.65 ± 0.34 | Rt (%) | 1.66 ± 0.42 | 1.59 ± 0.36 | 1.53 ± 0.41 | 1.60 ± 0.41 | 1.58 ± 0.41 | 1.66 ± 0.40 | HCT (%) | 38.38 ± 3.39 | 42.52** ± 1.77 | 40.65 ± 1.39 | 39.62 ± 2.47 | 45.58 ± 3.73 | 46.06 ± 2.30 | MCV (m3) | 55.01 ± 2.26 | 50.04** ± 2.23 | 54.33 ± 3.21 | 52.77 ±1.51 | 54.70 ± 2.40 | 53.26 ± 1.80 | MCH (pg) | 21.71 ± 0.98 | 18.09** ± 0.98 | 20.20** ± 1.29 | 19.81** ± 0.62 | 19.58 ±1.08 | 19.10 ± 0.75 | MCHC (%) | 39.48 ± 0.71 | 36.17** ± 0.54 | 37.15** ± 0.83 | 37.54** ± 0.36 | 35.80 ± 0.81 | 35.82 ± 0.33 | Platelets (×103/L) | 396.90 ± 38.04 | 399.70 ± 67.67 | 394.40 ± 69.40 | 404.10 ± 84.93 | 453.00 ± 32.61 | 443.40 ± 66.39 | Total WBC (×103/L) | 11.09 ± 2.94 | 12.52 ± 3.63 | 15.41* ± 4.79 | 13.53 ± 1.72 | 8.76 ± 2.06 | 10.84 ± 1.81 | N (%) | 21.60 ± 4.22 | 21.10 ± 2.92 | 20.90 ± 3.48 | 20.80 ± 4.49 | 20.40 ± 3.21 | 21.20 ± 3.11 | L (%) | 75.20 ± 3.99 | 75.90 ± 2.60 | 75.60 ± 3.57 | 76.20 ± 4.44 | 76.20 ± 2.95 | 75.80 ± 3.11 | E (%) | 1.50 ± 0.85 | 1.20 ± 0.79 | 1.10 ± 0.88 | 1.30 ± 0.82 | 1.20 ± 0.84 | 1.20 ± 0.84 | M (%) | 1.70 ± 0.95 | 1.80 ± 0.79 | 2.40 ± 0.84 | 1.70 ± 1.25 | 2.20 ± 0.84 | 1.80 ± 1.48 | B (%) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | Pt (s) | 14.80 ± 2.44 | 14.60 ± 2.27 | 15.10 ± 2.77 | 15.30 ± 2.54 | 15.20 ± 2.39 | 15.60 ± 3.13 |
|
|
P < 0.05 versus control group. P < 0.01 versus control group.
|